[1] Ogden CL,Carroll MD,Kit BK,et al.Prevalence of obesity and trends in body mass index among US children and adolescents,1999-2010[J].JAMA,2012,307(5):483-490. [2] Babinska K,Kovacs L,Janko V,et al.Association between obesity and the severity of ambulatory hypertension in children and adolescents[J].J Am Soc Hypertens,2012,6(5):356-363. [3] Vlachopoulos C,Gravos A,Georgiopoulos G,et al.The effect of TNF-α antagonists on aortic stiffness and wave reflections:a meta-analysis[J].Clin Rheumatol,2018,37(2):515-526. [4] Haapakoski R,Mathieu J,Ebmeier KP,et al.Cumulative meta-analysis of interleukins 6 and 1β,tumour necrosis factor α and C-reactive protein in patients with major depressive disorder[J].Brain Behav Immun,2015,49:206-215 [5] Sahebkar A,Serban C,Ursoniu S,et al.Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-Results from a systematic review and meta-analysis of randomized controlled trials[J].Int J Cardiol,2015,189:47-55. [6] Laine P,Pentikainen MO,Wurzner R,et al.Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction[J].Am J Cardiol, 2012,90(4):404-408. [7] 米杰.我国高血压的防治必须从儿童抓起[J].中华预防医学杂志,2014,48(5):337-339. [8] Caillon A,Schiffrin EL.Role of inflammation and immunity in hypertension:recent epidemiological,laboratory,and clinical evidence[J].Curr Hypertens Rep,2016,18(3):21. [9] Qian YS,Tang XF,Zhang J,et al.C-reactive protein (CRP) gene polymorphisms,CRP levels and risk of incident essential hypertension:findings from an observational cohort of Han Chinese[J].Hypertens Res,2012,35(10):1019-1023. [10] Hage FG.C-reactive protein and hypertension[J].J Hum Hypertens,2014,28(7):410. [11] Yao Y,Chang W,Jin Y.Association between TNF-a promoter-308G/A polymorphism and essential hypertension in the Asian population:a meta-analysis[J].J Renin Angiotensin Aldosterone Syst,2017,18(4):1-6. [12] Vidal F,Fontes TV,Marques TV F,et al.Association between apical periodontitis lesions and plasmatic levels of C-reactive protein,interleukin 6 and fibrinogen in hypertensive patients[J].Int Endod J,2016,49(12):1107-1115. [13] Chen J,Han L,Xu X,et al.Serum biomarkers VEGF-C and IL-6 are associated with severe human peripheral artery stenosis[J].J Inflamm,2015,12(1):50. [14] Jasiewicz M,Knapp M,Waszkiewicz E,et al.Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage[J].Cytokine,2015,76(2):187-192. [15] Wenzel UO,Bode M,Khl J,et al.A pathogenic role of complement in arterial hypertension and hypertensive end organ damage[J].Am J Physiol Heart Circ Physiol,2017,312(3):H349-H354. [16] Ruan CC,Ma Y,Ge Q,et al.Complement-mediated inhibition of adiponectin regulates perivascular inflammation and vascular injury in hypertension[J].FASEB J,2017,31(3):1120-1129. [17] Iyer A,Woodruff TM,Wu MC L,et al.Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats[J].J Cardiovasc Pharmacol,2015,58(5):479-486. |